Abbott Laboratories (ABT) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q4 26	$1.28	$1.31	+2.3%	—	—	—
Q3 26	$1.49	$1.5	+0.7%	—	—	—
Q2 26	$1.3	$1.3	0.0%	—	—	—
Q1 26	$1.26	$1.26	0.0%	—	—	—
Q4 25	$1.07	$1.09	+1.9%	—	—	—
Q3 25	$1.34	$1.34	0.0%	—	—	—
Q2 25	$1.2	$1.21	+0.8%	—	—	—
Q1 25	$1.1	$1.14	+3.6%	—	—	—
Q4 24	$0.95	$0.98	+3.2%	—	—	—
Q3 24	$1.19	$1.19	0.0%	—	—	—
Q2 24	$1.1	$1.14	+3.6%	—	—	—
Q1 24	$1.05	$1.08	+2.9%	—	—	—
Q4 23	$0.99	$1.03	+4.0%	—	—	—
Q3 23	$0.94	$1.03	+9.6%	—	—	—
Q2 23	$0.94	$1.15	+22.3%	—	—	—
Q1 23	$1.14	$1.43	+25.4%	—	—	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$3.76	—	—	$44.3B	—
FY24	—	$7.74	—	—	$42B	—
FY23	—	$3.3	—	—	$40.1B	—
FY22	—	$3.99	—	—	$43.7B

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$20.9B	$27.4B	$30.6B	$31.9B	$34.6B	$43.1B	$43.7B	$40.1B	$42B	$44.3B
YoY change	+2.2%	+31.3%	+11.6%	+4.34%	+8.48%	+24.5%	+1.34%	-8.12%	+4.59%	+5.67%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	20.9B	27.4B	30.6B	31.9B	34.6B	43.1B	43.7B	40.1B	42B	44.3B
Cost of revenue	9.1B	12.4B	12.7B	13.2B	15B	18.5B	19.1B	18B	18.7B	19.3B
Gross profit	11.8B	15B	17.9B	18.7B	19.6B	24.5B	24.5B	22.1B	23.2B	25B
Gross margin	56.4%	54.7%	58.4%	58.5%	56.6%	57%	56.1%	55.2%	55.4%	56.4%
Research & development	1.4B	2.3B	2.3B	2.4B	2.4B	2.7B	2.9B	2.7B	2.8B	2.9B
Selling, general & administrative	6.7B	9.2B	9.7B	9.8B	9.7B	11.3B	11.2B	10.9B	11.7B	12.3B
Operating expenses	8.2B	11.4B	12B	12.2B	12.1B	14.1B	14.1B	13.7B	14.5B	15.3B
Operating income	3B	1.6B	3.6B	4.5B	5.4B	8.4B	8.4B	6.5B	6.8B	8.1B
Operating margin	14.5%	5.71%	11.9%	14.2%	15.5%	19.6%	19.2%	16.2%	16.3%	18.2%
Non-operating income, net	-1.3B	1.4B	-56M	121M	111M	276M	319M	438M	403M	598M
Pretax income	1.4B	2.2B	2.9B	4.1B	5B	8.2B	8.3B	6.7B	7B	8.5B
Income tax	350M	1.9B	539M	390M	497M	1.1B	1.4B	941M	-6.4B	1.9B
Net income	1.4B	477M	2.4B	3.7B	4.5B	7.1B	6.9B	5.7B	13.4B	6.5B
Net margin	6.71%	1.74%	7.74%	11.6%	13%	16.4%	15.9%	14.3%	31.9%	14.7%
EBITDA	3.7B	6.1B	7.2B	7.8B	8.8B	12.3B	12.1B	10.6B	10.8B	12B
EPS	0.95	0.27	1.35	2.09	2.54	4.01	3.99	3.3	7.74	3.76
Diluted EPS	0.94	0.27	1.33	2.06	2.5	3.94	3.91	3.26	7.64	3.72

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	10.1B	10.2B	10B	10.4B	10.6B	11B	10.4B	11.1B	11.4B	11.5B	11.2B	—
Cost of revenue	4.6B	4.6B	4.5B	4.6B	4.7B	4.9B	4.5B	4.9B	5.1B	4.9B	4.9B	—
Gross profit	5.5B	5.7B	5.5B	5.8B	5.9B	6B	5.9B	6.3B	6.3B	6.5B	6.3B	—
Gross margin	54.6%	55.5%	55.2%	55.6%	55.8%	55%	56.9%	56.4%	55.4%	57%	56.2%	—
Research & development	672M	700M	684M	698M	713M	749M	716M	725M	766M	735M	767M	—
Selling, general & administrative	2.7B	2.7B	3B	2.9B	2.9B	2.9B	3.1B	3.1B	3.1B	3.1B	3.7B	—
Operating expenses	3.4B	3.4B	3.6B	3.6B	3.6B	3.7B	3.8B	3.8B	3.8B	3.9B	4.5B	—
Operating income	1.6B	1.8B	1.4B	1.7B	1.9B	1.9B	1.7B	2.1B	2.1B	2.3B	1.3B	—
Operating margin	16.2%	17.4%	13.9%	16.1%	17.5%	17.4%	16.3%	18.4%	18.1%	19.6%	12%	—
Non-operating income, net	93M	85M	111M	-4M	132M	164M	134M	148M	167M	149M	172M	—
Pretax income	1.7B	1.8B	1.4B	1.6B	1.9B	2B	1.8B	2.1B	2.2B	2.4B	1.4B	—
Income tax	235M	201M	211M	305M	294M	-7.2B	453M	371M	536M	582M	372M	—
Net income	1.4B	1.6B	1.2B	1.3B	1.6B	9.2B	1.3B	1.8B	1.6B	1.8B	1.1B	—
Net margin	14.2%	15.6%	12.3%	12.5%	15.5%	84.1%	12.8%	16%	14.5%	15.5%	9.65%	—
EBITDA	2.7B	2.8B	2.4B	2.5B	2.9B	3B	2.7B	3B	3.1B	3.3B	2.4B	—
EPS	0.83	0.92	0.7	0.75	0.95	5.33	0.76	1.02	0.95	1.02	0.62	0.53
Diluted EPS	0.82	0.91	0.7	0.74	0.94	5.27	0.76	1.01	0.94	1.01	0.61	0.53

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	56.6B	—	127B	153.1B	193.9B	248.3B	190.8B	190.9B	195.9B	217.6B	186.8B
Enterprise value	59.8B	—	142.5B	167.8B	206.4B	257B	198.3B	199.2B	202.9B	222.5B	210.7B
Shares outstanding	1.5B	1.7B	1.8B	1.8B	1.8B	1.8B	1.7B	1.7B	1.7B	1.7B	1.7B

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	40.4	—	53.6	41.5	43.1	35.1	27.5	33.4	14.6	33.4	34.1
P/S	2.71	—	4.15	4.8	5.6	5.76	4.37	4.76	4.67	4.91	3.93
P/B	2.73	—	4.13	4.89	5.88	6.89	5.17	4.92	4.09	4.12	3.58
EV/EBITDA	16.2	—	19.9	21.4	23.4	20.9	16.3	18.8	18.9	18.5	18
EV/Sales	2.87	—	4.66	5.26	5.96	5.97	4.54	4.97	4.84	5.02	4.52
Earnings yield	2.47%	—	1.86%	2.41%	2.32%	2.85%	3.63%	3%	6.84%	3%	2.93%
FCF yield	3.68%	—	3.86%	2.94%	2.95%	3.48%	4.09%	2.65%	3.24%	3.4%	3.86%
PEG	—	—	—	—	—	—	—	—	—	—	-0.71

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	56.4%	54.7%	58.4%	58.5%	56.6%	57%	56.1%	55.2%	55.4%	56.4%	56.3%
Operating margin	14.5%	5.71%	11.9%	14.2%	15.5%	19.6%	19.2%	16.2%	16.3%	18.2%	14.7%
Net margin	6.71%	1.74%	7.74%	11.6%	13%	16.4%	15.9%	14.3%	31.9%	14.7%	11.6%
ROE	6.76%	1.53%	7.71%	11.8%	13.6%	19.6%	18.8%	14.7%	28%	12.4%	10.6%
ROA	2.66%	0.63%	3.53%	5.43%	6.2%	9.4%	9.31%	7.82%	16.5%	7.52%	5.33%
ROIC	9.51%	0.5%	6.42%	8.9%	10.6%	16.2%	15.7%	11.8%	12.4%	10.8%	7.48%
Return on tangible assets	4.96%	-3.24%	-13.8%	-29.4%	-99.7%	217.2%	87.4%	69.6%	61.2%	23.6%	148.1%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	4.02	2.26	1.62	1.44	1.72	1.85	1.63	1.64	1.67	1.58	1.38
Quick ratio	3.65	1.86	1.2	1.04	1.3	1.46	1.23	1.16	1.23	1.18	1.01
Debt / equity	1.06	0.9	0.64	0.6	0.6	0.53	0.48	0.4	0.31	0.26	0.63
Debt / assets	0.42	0.37	0.29	0.28	0.27	0.25	0.24	0.21	0.18	0.16	0.31
Net debt / EBITDA	0.88	2.99	2.16	1.88	1.42	0.71	0.62	0.79	0.66	0.41	2.27
Interest coverage	4.28	3.47	4.48	7.09	10.1	16.4	15.9	11.5	13.5	18.2	16.2
Effective tax rate	24.8%	84.2%	18.8%	9.57%	10%	13.9%	16.5%	14.1%	0%	22.9%	22.9%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	14.2	15.7	17.4	18.1	19.5	24.4	25.1	23.1	24.2	25.5	26.8
EPS (basic)	0.95	0.27	1.35	2.09	2.54	4.01	3.99	3.3	7.74	3.76	3.76
EPS (diluted)	0.94	0.27	1.33	2.06	2.5	3.94	3.91	3.26	7.64	3.72	3.1
Book value per share	14.1	17.8	17.5	17.8	18.6	20.4	21.2	22.4	27.7	30.4	29.5
FCF per share	1.41	2.54	2.79	2.55	3.23	4.9	4.49	2.92	3.67	4.26	4.22
Cash per share	12.7	5.51	2.33	2.35	4.04	5.81	5.85	4.2	4.6	5.15	3.24
Capex per share	0.76	0.65	0.79	0.93	1.23	1.07	1.02	1.27	1.27	—	1.19

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	5.38%	4.14%	4.56%	5.13%	6.29%	4.38%	4.07%	5.49%	5.26%	—	4.62%
Capex / operating cash flow	48.7%	20.7%	22.5%	24.9%	25%	17.5%	18.8%	28.7%	13.1%	—	22.5%
Payout ratio	109.9%	387.6%	83.4%	61.6%	57%	45.3%	47.7%	62.1%	28.6%	63.1%	79%
Dividend yield	2.72%	—	1.55%	1.48%	1.32%	1.29%	1.73%	1.86%	1.96%	1.89%	2.33%

Yield

2.33%

trailing twelve months

Frequency

Quarterly

Last dividend

$0.63

ex-dividend Jul 15, 2026

Payout ratio

79%

of earnings

Dividend growth

12 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
Jul 15, 2026	$0.63
Apr 15, 2026	$0.63
Jan 15, 2026	$0.63

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$10.1B	$10.2B	$10B	$10.4B	$10.6B	$11B	$10.4B	$11.1B	$11.4B	$11.5B	$11.2B	—
YoY change	-2.56%	+1.49%	+2.23%	+4%	+4.85%	+7.16%	+3.95%	+7.37%	+6.9%	+4.42%	+7.78%	—

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	18.8B	9.6B	4.1B	4.1B	7.1B	10.2B	10.2B	7.3B	8B	8.9B
Receivables	3.2B	5.2B	5.2B	5.4B	6.4B	6.5B	6.2B	6.6B	6.9B	7.9B
Inventory	2.4B	3.6B	3.8B	4.3B	5B	5.2B	6.2B	6.6B	6.2B	6.5B
Total current assets	26.8B	20.1B	14.6B	15.7B	20.4B	24.2B	25.2B	22.7B	23.7B	26B
Property, plant & equipment	3.1B	4B	4B	4.3B	5B	18.5B	5.1B	6B	6.5B	7.3B
Goodwill & intangibles	24.4B	91B	84.4B	80.4B	77.1B	71.9B	66.5B	65B	59.5B	59.1B
Total assets	52.7B	76.3B	67.2B	67.9B	72.5B	75.2B	74.4B	73.2B	81.4B	86.7B
Accounts payable	1.2B	2.4B	3B	3.3B	3.9B	4.4B	4.6B	4.3B	4.2B	4.2B
Short-term debt	1.3B	714M	207M	1.5B	220M	754M	2.3B	1.1B	1.5B	3B
Total current liabilities	6.7B	8.9B	9B	10.9B	11.9B	13.1B	15.5B	13.8B	14.2B	16.5B
Long-term debt	20.7B	27.2B	19.4B	17.4B	19.4B	18.3B	15.5B	14.5B	13.5B	10.8B
Total liabilities	31.9B	45.2B	36.5B	36.6B	39.5B	39.2B	37.5B	34.4B	33.5B	33.9B
Shareholders' equity	20.7B	31.1B	30.7B	31.3B	33B	36B	36.9B	38.8B	47.9B	52.8B
Total debt	22B	27.9B	19.6B	18.9B	19.6B	19B	17.7B	15.6B	15B	13.9B
Net debt	3.4B	18.5B	15.7B	15B	12.8B	9.2B	7.8B	8.7B	7.4B	5.3B

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Cash & short-term investments	8.2B	7B	7.3B	6.7B	7.2B	7.8B	8B	6.8B	7.3B	7.7B	8.9B	7.3B
Receivables	6.2B	6.5B	6.6B	6.6B	6.9B	7.1B	6.9B	7.3B	8B	8.1B	7.9B	8.2B
Inventory	6.9B	6.7B	6.6B	6.8B	6.8B	6.8B	6.2B	6.6B	7B	6.7B	6.5B	7B
Total current assets	23.5B	22.7B	22.7B	22.4B	23.1B	23.8B	23.7B	23.2B	24.5B	24.8B	26B	25.5B
Property, plant & equipment	-11.5B	-11.6B	6B	-11.9B	-11.8B	-12.2B	6.5B	-12.5B	-13.1B	-13.3B	7.3B	-13.4B
Goodwill & intangibles	66.2B	65.1B	65B	63.4B	62.3B	62B	59.5B	59.2B	59.7B	59.1B	59.1B	106.2B
Total assets	73.4B	72.1B	73.2B	72.5B	73B	74.4B	81.4B	81.4B	84B	84.2B	86.7B	110.4B
Accounts payable	4.2B	4B	4.3B	4.2B	4.1B	4B	4.2B	4.2B	4.3B	4.1B	4.2B	4.7B
Short-term debt	2.3B	1.1B	1.1B	2B	1.6B	2.2B	1.5B	506M	507M	1.3B	3B	4.4B
Total current liabilities	14.3B	13B	13.8B	14B	13.8B	14.9B	14.2B	13B	13.4B	14.6B	16.5B	18.4B
Long-term debt	14.6B	14.5B	14.5B	12.6B	13.1B	12.8B	13.5B	12.7B	12.9B	11.6B	10.8B	29.6B
Total liabilities	36B	34.4B	34.4B	33.4B	33.5B	34.3B	33.5B	32.4B	33.2B	32.9B	33.9B	57.7B
Shareholders' equity	37.4B	37.7B	38.8B	39B	39.6B	40B	47.9B	49.1B	50.8B	51.3B	52.8B	52.7B
Total debt	16.8B	15.5B	15.6B	14.6B	14.8B	15B	15B	13.2B	13.4B	12.9B	13.9B	34B
Net debt	9B	8.8B	8.7B	8.3B	7.8B	7.4B	7.4B	6.7B	6.5B	5.4B	5.3B	27.2B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	1.4B	477M	2.4B	3.7B	4.5B	7.1B	6.9B	5.7B	13.4B	6.5B
Depreciation & amortization	1.4B	3B	3.3B	3B	3.3B	3.5B	3.3B	3.2B	3.2B	3.1B
Stock-based compensation	310M	406M	477M	519M	546M	640M	685M	644M	673M	664M
Change in working capital	-927M	657M	43M	-648M	349M	-459M	-1.4B	-1.9B	-393M	497M
Operating cash flow	2.3B	5.5B	6.2B	6.6B	8.7B	10.8B	9.4B	7.7B	16.9B	9.6B
Capital expenditure	-1.1B	-1.1B	-1.4B	-1.6B	-2.2B	-1.9B	-1.8B	-2.2B	-2.2B	—
Investing cash flow	-248M	-9.6B	-1.4B	-1.8B	-2.2B	-2B	-1.7B	-3.1B	-2.3B	-251M
Dividends paid	-1.5B	-1.8B	-2B	-2.3B	-2.6B	-3.2B	-3.3B	-3.6B	-3.8B	-4.1B
Share repurchases	-522M	-827M	-238M	-718M	-403M	-2.3B	-3.8B	-1.2B	-1.3B	-893M
Financing cash flow	10.9B	-5.6B	-10.7B	-4.6B	-3B	-5.7B	-7.8B	-7.3B	-5.7B	-6.7B
Net change in cash	13B	-9.8B	-5.8B	170M	3.5B	3B	-102M	-2.7B	8.9B	2.6B
Free cash flow	2.1B	4.4B	4.9B	4.5B	5.7B	8.6B	7.8B	5.1B	6.4B	7.4B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Net income	1.4B	1.4B	1.6B	1.2B	1.3B	1.6B	9.2B	1.3B	1.8B	1.6B	1.8B	1.1B
Depreciation & amortization	800M	824M	813M	805M	805M	801M	807M	756M	777M	791M	792M	803M
Stock-based compensation	132M	117M	114M	304M	141M	117M	111M	289M	142M	120M	113M	317M
Change in working capital	-444M	-321M	363M	-561M	-428M	163M	77M	-517M	-407M	11M	456M	-462M
Operating cash flow	1.2B	1.9B	2.9B	1B	2B	2.7B	10.2B	1.4B	2B	2.8B	3.3B	1.3B
Capital expenditure	-507M	-560M	-755M	-398M	-533M	-556M	-720M	-484M	-502M	—	—	—
Investing cash flow	-506M	-596M	-753M	-397M	-531M	-554M	-716M	-478M	-530M	-51M	-14M	-19.8B
Dividends paid	-890M	-888M	-888M	-957M	-961M	-960M	-958M	-1B	-1B	-1B	-1B	-1.1B
Share repurchases	-426M	-2M	-259M	-226M	-3M	-751M	-315M	-280M	-6M	-305M	-302M	-180M
Financing cash flow	-1.3B	-2.4B	-2.1B	-1.3B	-804M	-1.7B	-1.9B	-2.3B	-1.1B	-1.8B	-1.4B	17.2B
Net change in cash	-608M	-1.1B	45M	-682M	625M	483M	7.6B	-1.4B	467M	907M	1.9B	-1.3B
Free cash flow	696M	1.3B	2.3B	627M	1.4B	2.1B	2.1B	933M	1.5B	2.3B	2.6B	916M

Date	Ratio
Jan 2, 2013	10000:4798
May 3, 2004	10000:9356
Jun 1, 1998	2:1
Jun 1, 1992	2:1
Jun 1, 1990	2:1
Jun 2, 1986	2:1
Jun 1, 1981	2:1

Abbott Laboratories Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement

Split history